Papp K, Maari C, Cauthen A, et al. - In the integrated data from UNCOVER-1, -2 and -3 studies among patients who had static Physician’s Global Assessment (sPGA) > 1 at Week 12, efficiency through Week 52 of continuous Q2W dosing in the IXORA-P study was contrasted indirectly with Q2W/Q4W and it was evaluated whether patients with sPGA > 1 at Week 12 profited from receiving more regular dosing beyond the first 12 weeks. According to findings, nearly 30% more patients treated continuously with ixekizumab Q2W in IXORA-P had clear or almost clear skin at Week 52 when compared indirectly with those treated with labeled psoriasis dosing in integrated UNCOVER studies among patients who did not have clear or almost clear skin at Week 12.